A meta-analysis of serious infections in 9 randomized controlled trials with the anti-TNF antibodies infliximab and adalimumab found an odds ratio of serious infections of 2.01 (95% CI 1.31-3.09) for patients treated with anti-TNF anti-bodies for at least 12 weeks, in comparison with a control population treated with placebo or placebo in combination with DMARDs [11]. The gene discussed is TNF; the disease is infection.